ESR1 and neoplasm: Moreover, in vitro data have shown that increased MAPK pathway signalling can promote the loss of ERα expression in breast cancer tumours [25], which may contribute to the poor responses to ET observed in patients whose tumours harbour alterations in genes associated with the MAPK pathway [3].